Daniel Ian Abrams

20070191695, Aug 16, 2007

Dec 6, 2006

11/567597

Daniel Abrams - Denver CO, US
Christopher Crowley - Golden CO, US
Kevin Keilbach - Boulder CO, US

A61B 5/00

600310000

A patient is monitored during a medical procedure, such as spinal surgery, to identify a condition indicative of the possible onset of blindness or damage to the patient's eye or eyes. Parameters that may be monitored in this regard include ocular perfusion, retinal oxygen saturation and ocular pressure. In one implementation, a device for monitoring the desired parameters includes a contact lens with fiber optic pathways mounted thereon. Light of multiple wavelengths can be transmitted into the patient's eyes via input optical pathways. Output optical pathways are associated with a camera for obtaining images of an area of interest within the patient's eyes. The images can be processed to obtain information regarding ocular perfusion and/or oxygen saturation. Changes in this regard can be used to identify a condition of interest.

20070198486, Aug 23, 2007

Aug 24, 2006

11/466826

Daniel Abrams - Los Angeles CA, US
Sami Vaaraniemi - Helsinki, FI

G06F 17/30

707003000

A system and method for searching the Internet is presented wherein the search results are ordered and selected using one or more preference tools. One such tool consists of the user defining a reference index number that is employed to prioritize and re-rank at least some of the sites obtained by the search, comparing each site's parameters to the reference index number. Each index number includes several parameters in a preset order, each parameter being assigned a quantized relevance based on particular search criteria. Another tool makes use of at least one bundle of websites having particular user-settings designating credibility or trustworthiness. Websites from the search results are then accepted or ordered based on the contents of the bundles. Other tools adjust search criteria based on a desired number of search results and separate browser cookies into (1) those personally trusted and (2) all other cookies that are routinely purged.

20070270673, Nov 22, 2007

Feb 15, 2007

11/675178

Daniel Abrams - Denver CO, US
Christopher Crowley - Golden CO, US
Kevin Keilbach - Boulder CO, US

A61B 5/00

600310000

A system and associated methodology allow for monitoring ocular parameters of a patient. Parameters that may be monitored in this regard include ocular perfusion, retinal oxygen saturation and ocular pressure. In one implementation, a device for monitoring the desired parameters includes a contact lens with fiber optic pathways mounted thereon. Light of multiple wavelengths can be transmitted into the patient's eyes via input optical pathways. Output optical pathways are associated with a camera for obtaining images of an area of interest within the patient's eyes. The images can be processed to obtain information regarding ocular perfusion and/or oxygen saturation. Changes in this regard can be used to identify a condition of interest.

20090069267, Mar 12, 2009

Jul 25, 2008

12/180373

Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US

A61K 31/7076
A61K 31/551
A61K 31/519
A61K 31/137
A61K 31/55
A61P 25/28

514 46, 514220, 51425941, 514651, 514217, 51421113

The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.

20090209480, Aug 20, 2009

Jan 17, 2007

12/161149

Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US

The Regents of the University of Colorado - Denver CO

A61K 31/7076
A61K 31/27
A61K 31/53
A61K 31/195
A61K 31/19
A61K 31/55
A61K 31/551
A61K 31/4178
A61K 31/135
A61P 25/18

514 46, 514483, 514242, 514562, 514557, 514217, 514220, 514397, 514646

The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.

20090221956, Sep 3, 2009

Jan 22, 2007

12/161302

Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Michael Royals - Pierce CO, US

The Regents of the University of Colorado - Denver CO

A61M 5/142

604 66

The invention generally relates to a multi-parameter monitoring device for in-line use to monitor a therapeutic agent solution passing therethrough prior to being centrally administered in connection with treatment of a CNS-related condition or disorder, e.g., a neuro-psychiatric disorder. In another aspect, the invention relates to a multi-parameter monitoring device for in-line use to monitor a therapeutic agent solution passing therethrough prior to being (a) intravenously administered to a patient in connection with a treatment, such as is the case where the therapeutic agent solution comprises an IV administerable solution, or (b) administered to a patient in connection with a treatment for diabetes, such as is the case where the therapeutic agent comprises insulin.

20120071432, Mar 22, 2012

Mar 18, 2011

13/051950

Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen Elizabeth Stevens - Westminster CO, US

The Regents of the University of Colorado - Denver CO

A61K 31/7076
A61K 31/53
A61K 31/196
A61K 31/55
A61K 31/19
A61K 31/551
A61K 31/4178
A61K 31/15
A61K 31/138
A61K 31/135
A61P 25/08
A61P 25/00
A61P 25/18
A61P 25/28
A61P 25/24
A61P 25/20
A61P 25/22
A61K 31/27

514 46, 514483, 514242, 514562, 514217, 514557, 514220, 514397, 514664, 514651, 514647, 514656

The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-ac-Live agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.

20220331567, Oct 20, 2022

Jul 1, 2022

17/856758

- Aurora CO, US
Daniel J. Abrams - Denver CO, US

Cerebral Therapeutics, Inc. - Aurora CO

A61M 27/00
A61M 5/142
A61M 5/165
A61M 5/158
A61M 39/02

An implantable cranial medical device includes a first fluid flow path, a second fluid flow path, and upper flange portion, and a lower portion. The upper flange portion is configured to rest on a skull of a subject about a burr hole. The lower portion is configured to be placed within the burr hole. The first fluid flow path may extend from a first opening in the upper flange portion to a first opening in the lower portion. The second fluid flow path may extend from a second opening in the upper flange portion to a second opening in the lower portion.